Adverse event detection in drug development: recommendations and obligations beyond phase 3.
暂无分享,去创建一个
[1] J. Drazen,et al. Blueprint for a stronger Food and Drug Administration. , 2006, The New England journal of medicine.
[2] A. Mitchell,et al. When a Randomised Controlled Trial is Needed to Assess Drug Safety , 1995, Drug safety.
[3] S. Ellenberg. Safety considerations for new vaccine development , 2001, Pharmacoepidemiology and drug safety.
[4] Andrew A. Signore,et al. Pharmaceutical Industry Profile , 2005 .
[5] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[6] A. Mitchell,et al. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. , 1995, JAMA.
[7] C. Stein,et al. Making medicines safer--the need for an independent drug safety board. , 1998, The New England journal of medicine.
[8] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[9] J. DiMasi. New drug development in the United States from 1963 to 1999 , 2001, Clinical pharmacology and therapeutics.
[10] J. Hasford. Drug risk assessment: A case for large trials with lean protocols , 1994 .
[11] J. Boivin,et al. Bias and Confounding in Pharmacoepidemiology , 2002 .
[12] Susan S Ellenberg,et al. Evaluating the safety of new vaccines: summary of a workshop. , 2005, American journal of public health.
[13] Peter A Gross,et al. The FDA and drug safety: a proposal for sweeping changes. , 2006, Archives of internal medicine.
[14] R. Coulson,et al. Revitalizing the General Practice Research Database: plans, challenges, and opportunities , 2001, Pharmacoepidemiology and drug safety.
[15] Corri Black,et al. Validity of the General Practice Research Database , 2003, Pharmacotherapy.
[16] B. Strom,et al. How the US drug safety system should be changed. , 2006, JAMA.
[17] W. DuMouchel,et al. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post‐marketing setting , 2003, Pharmacoepidemiology and drug safety.
[18] S. Gutthann,et al. Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.
[19] P. Rhodes,et al. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). , 1998, Journal of clinical epidemiology.
[20] R Peto,et al. Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.
[21] Syed Rizwanuddin Ahmad,et al. Adverse drug event monitoring at the food and drug administration , 2003, Journal of general internal medicine.
[22] M. Braun,et al. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. , 2001, Vaccine.
[23] C Michael Stein,et al. Reform of drug regulation--beyond an independent drug-safety board. , 2006, The New England journal of medicine.